

Finance and Performance Assurance Committee Key Issues Report

Report Date: 27 th October 2020		Report of: Finance and Performance Assurance Committee
Date of last meeting: 27 th October 2020		Membership Numbers: The meeting was quorate.
1	Agenda	<p>The Committee considered an agenda which included the following:</p> <ul style="list-style-type: none"> • Business Case – PCR Antigen Testing • Operational Performance Month 6 • Finance Report Month 6 • Medical Engineering Service – Revised Capital Programme • Capital Allocation MoU for approval for Urgent and Emergency Care Programme (SDEC) • Allocation of Funding to support International Nurse Recruitment • Post Project Review: Radiotherapy linac contract insourcing
2a	Alert	<p>The Committee wish to alert members of the Board that:</p> <ul style="list-style-type: none"> • In terms of recovery of elective services from a system and SaTH perspective, it had not been possible to meet all national expectations in terms of % delivery, particularly with regard to Endoscopy and Radiology (MRI). However, day case, inpatients, outpatients and CT were all performing slightly above plan. • The Committee acknowledged the likelihood of a reduction on elective activity during the winter and noted the significant impact this would have on RTT performance. • A&E demand continues to rise with activity returning close to pre-COVID-19 levels. It is expected that the new ambulatory care facility at RSH, due to become operational at Xmas, will assist with this, however the Trust is predicting a disappointing performance during winter. • Both ambulance handovers and 12 hour breaches were areas the Trust was closely monitoring. With regard to the latter there was potential for these to be similar to last year's levels in November/December although the Trust was doing all it could to mitigate this. • The committee noted the allocation of £6,300,000 PDC to provide Same Day Emergency Centre modular build and refurbish the existing Emergency Department at RSH and £233,356 to support international nursing recruitment and recommended retrospective approval (due to timescales) of the signing of the MOUs by the Board of Directors.
2b	Assurance	<ul style="list-style-type: none"> • The Committee was assured that cancer performance remains a top priority for the Trust and in general the Trust was performing well against cancer targets. Significant work was taking place to reduce the 62 day and 104 day backlogs.

		<ul style="list-style-type: none"> The Committee welcomed colleagues from the Radiotherapy Department who attended the meeting to share the outcomes of a post project evaluation following the completion of a project to bring the Varian linac contracts in-house and was assured by the success of this.
2c	Advise	<p>The Committee wish to advise members of the Board that:</p> <ul style="list-style-type: none"> The Committee considered a business case for PCR Antigen Testing for SARS, COVID-19 which would increase the Trust's swabbing and testing capacity through additional staffing resources and equipment. In recognition of the short timeframe for approval and implementation, the committee recommended approval of the business case by the Board of Directors but asked for advanced notification of these in future. The committee was advised of another national project whereby a short timeframe for approval and implementation was expected relating to vaccination. In terms of diagnostic performance, it was hoped that with the additional equipment, the Trust would start to recover the position with a view to reducing the waiting list for imaging. The Trust reported a break even position for the month of September 2020 with additional NHSE/I support. There was a considerable variance to the deficit position in month of £4.3 million due to a number of factors including COVID-19 costs, medical consultant pay award and N365. A forecast outturn position for the year 2020/21 of a deficit of £7.724 million was submitted to NHSE/I on 22nd October 2020 as agreed. An update on the cash and capital position was provided and it was noted that a significant amount of the capital budget would be expended towards the end of the financial year. The committee was advised of external MoU funding being received for projects including Adopt and Adapt funding (£2,811,000 to be confirmed), Critical Care Resilience Funding (£350,000) to be spent primarily on the purchase of bioquell pods. In addition the committee was informed of the proposal to allocate, from the capital backlog element of the capital plan, the sum of £181,000 and £300,000 respectively for RSH and PRH DSUs. This was supported by the Committee. The committee received and approved a revision to the medical device replacement programme (see Appendix 1) as part of the Capital Programme that would replace all SaTH anaesthetic machines this financial year with high specification devices.
2d	Review of Risks	Due to the review of the risk and BAF process taking place, the BAF was not considered on this occasion.
3	Actions to be considered by the Board	<ul style="list-style-type: none"> Committee Summary to be noted. Consideration and approval of: <ul style="list-style-type: none"> Business Case – PCR Antigen Testing Capital Allocation for Urgent and Emergency Care Programme (SDEC) MOU

		<ul style="list-style-type: none"> ○ Allocation of Funding to support International Nurse Recruitment MOU 		
4	Report compiled by	<i>Clive Deadman Chair of Committee</i>	Minutes available from	<i>Amanda Young Committee Support</i>

Appendix 1 – Revised programme for Medical Devices

Project	Approved Sum	Expenditure to date	Total Projected Expenditure	Variance
	£	£	£	£
MES Schemes				
MES1 - Replacement Programme - Ultrasound Scanners	889,000	0	855,001	33,999
Total MES1 - Replacement Programme - Ultrasound Scanners	889,000	0	855,001	33,999
MES2 - Replacement Programme -Theatre Camera Stacks	650,000	472,176	472,176	177,824
Total MES2 - Replacement Programme -Theatre Camera Stacks	650,000	472,176	472,176	177,824
MES3 - Replacement Programme - Incubators	510,000	0	218,741	291,259
Total MES3 - Replacement Programme - Incubators	510,000	0	218,741	291,259
MES4 - Replacement Programme - Anaesthetic Machines	300,000	0	1,113,518	-813,518
Total MES4 - Replacement Programme - Anaesthetic Machines	300,000	0	1,113,518	-813,518
MES5 - Replacement Programme - Diathermy	176,000	0	280,199	-104,199
Total MES5 - Replacement Programme - Diathermy	176,000	0	280,199	-104,199
MES6 - Replacement Programme - various				
Central Station RSH PRH x6 (yr1)	90,000	0	0	90,000
R.O. Unit (RSH ITU) (Yr1)	50,000	0	50,000	0
Lasers (Yr 2)	200,000	0	60,000	140,000
Transport Trolley's RSH PRH (Yr 2)	30,000	0	30,000	0
Flexible Endoscopes	250,000	0	0	250,000
Rigid Telescopes	40,000	0	40,000	0
Suction Controllers x 250	25,000	0	25,000	0
Bladder Scanners x 3	30,000	0	32,796	-2,796
Dialysis Machines x 10	150,000	0	150,000	0
R.O.Unit (Ludlow)	48,000	0	60,000	-12,000
Dialysis Multifiltratie x 2	30,000	0	0	30,000
Total MES6 - Replacement Programme - various	943,000	0	447,796	495,204
MES7 - In House costs of delivery of schemes	50,000	4,972	30,449	19,551
Total 'MES7 - In House costs of delivery of schemes	50,000	4,972	30,449	19,551
MES8 - Schemes brought forward			0	
Radiotherapy System Upgrade	9,000	7,901	9,000	0
Eye Injection Automation System (PC)	32,000	196	32,000	0
Total MES8 - Schemes brought forward	41,000	8,097	41,000	0
Total MES	3,559,000	485,245	3,458,880	100,119